81 related articles for article (PubMed ID: 23539389)
21. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer.
Ramanathan RK; Clark JW; Kemeny NE; Lenz HJ; Gococo KO; Haller DG; Mitchell EP; Kardinal CG
J Clin Oncol; 2003 Aug; 21(15):2904-11. PubMed ID: 12885808
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil.
de Angelis PM; Fjell B; Kravik KL; Haug T; Tunheim SH; Reichelt W; Beigi M; Clausen OP; Galteland E; Stokke T
Int J Oncol; 2004 May; 24(5):1279-88. PubMed ID: 15067352
[TBL] [Abstract][Full Text] [Related]
23. Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues.
Tong M; Zheng W; Lu X; Ao L; Li X; Guan Q; Cai H; Li M; Yan H; Guo Y; Chi P; Guo Z
Oncotarget; 2015 Dec; 6(38):41216-27. PubMed ID: 26515599
[TBL] [Abstract][Full Text] [Related]
24. Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells.
Fiore D; Proto MC; Pisanti S; Picardi P; Pagano Zottola AC; Butini S; Gemma S; Casagni A; Laezza C; Vitale M; Ligresti A; Di Marzo V; Zisterer DM; Nathwani S; Williams DC; Campiani G; Gazzerro P; Bifulco M
Cancer Biol Ther; 2016 Aug; 17(8):849-58. PubMed ID: 26392056
[TBL] [Abstract][Full Text] [Related]
25. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
Capitain O; Asevoaia A; Boisdron-Celle M; Poirier AL; Morel A; Gamelin E
Clin Colorectal Cancer; 2012 Dec; 11(4):263-7. PubMed ID: 22683364
[TBL] [Abstract][Full Text] [Related]
26. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
Réti A; Pap E; Adleff V; Jeney A; Kralovánszky J; Budai B
Cancer Chemother Pharmacol; 2010 Jul; 66(2):219-27. PubMed ID: 19830428
[TBL] [Abstract][Full Text] [Related]
27. Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines.
Kawabata R; Oie S; Takahashi M; Kanayama H; Oka T; Itoh K
Int J Oncol; 2011 Jun; 38(6):1489-500. PubMed ID: 21455575
[TBL] [Abstract][Full Text] [Related]
28. Induction of apoptosis and suppression of ERCC1 expression by the potent amonafide analogue 8-c in human colorectal carcinoma cells.
Wang Z; Liang X; Cheng Z; Xu Y; Yin P; Zhu H; Li Q; Qian X; Liu J
Anticancer Drugs; 2013 Apr; 24(4):355-65. PubMed ID: 23426174
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro.
Arul M; Roslani AC; Cheah SH
In Vitro Cell Dev Biol Anim; 2017 May; 53(5):435-447. PubMed ID: 28120247
[TBL] [Abstract][Full Text] [Related]
30. Lupeol alters ER stress-signaling pathway by downregulating ABCG2 expression to induce Oxaliplatin-resistant LoVo colorectal cancer cell apoptosis.
Chen MC; Hsu HH; Chu YY; Cheng SF; Shen CY; Lin YJ; Chen RJ; Viswanadha VP; Lin YM; Huang CY
Environ Toxicol; 2018 May; 33(5):587-593. PubMed ID: 29436100
[TBL] [Abstract][Full Text] [Related]
31. Apoptotic effect of 5-fluorouracil-doxorubicin combination on colorectal cancer cell monolayers and spheroids.
Bilgin S
Mol Biol Rep; 2024 May; 51(1):603. PubMed ID: 38698270
[TBL] [Abstract][Full Text] [Related]
32. Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
Wang X; Zuo D; Chen Y; Li W; Liu R; He Y; Ren L; Zhou L; Deng T; Wang X; Ying G; Ba Y
Br J Cancer; 2014 Nov; 111(10):1965-76. PubMed ID: 25321193
[TBL] [Abstract][Full Text] [Related]
33. In vitro antiproliferative characteristics of flavonoids and diazepam on SNU-C4 colorectal adenocarcinoma cells.
Lee SW; Lee JT; Lee MG; Lee HW; Ahn SJ; Lee YJ; Lee YL; Yoo J; Ahn BC; Ha JH
J Nat Med; 2009 Apr; 63(2):124-9. PubMed ID: 19050992
[TBL] [Abstract][Full Text] [Related]
34. Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model.
Zhu G; Zhao M; Han Q; Tan Y; Sun YU; Bouvet M; Singh SR; Ye J; Hoffman RM
Anticancer Res; 2019 Nov; 39(11):5999-6005. PubMed ID: 31704825
[TBL] [Abstract][Full Text] [Related]
35. Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation.
Pangeni R; Choi SW; Jeon OC; Byun Y; Park JW
Int J Nanomedicine; 2016; 11():6379-6399. PubMed ID: 27942212
[TBL] [Abstract][Full Text] [Related]
36. EGCG synergizes the therapeutic effect of cisplatin and oxaliplatin through autophagic pathway in human colorectal cancer cells.
Hu F; Wei F; Wang Y; Wu B; Fang Y; Xiong B
J Pharmacol Sci; 2015 May; 128(1):27-34. PubMed ID: 26003085
[TBL] [Abstract][Full Text] [Related]
37. Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis.
Park M; Sundaramoorthy P; Sim JJ; Jeong KY; Kim HM
Anticancer Res; 2017 Jan; 37(1):103-114. PubMed ID: 28011480
[TBL] [Abstract][Full Text] [Related]
38. Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer.
Yu C; Liu SL; Qi MH; Zou X
Mol Med Rep; 2014 Feb; 9(2):669-76. PubMed ID: 24276478
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of anticancer efficacy of chemotherapeutics by gambogic acid against gastric cancer cells.
Zou ZY; Wei J; Li XL; Yu LX; Wang TT; Qian XP; Liu BR
Cancer Biother Radiopharm; 2012 Jun; 27(5):299-306. PubMed ID: 22444164
[TBL] [Abstract][Full Text] [Related]
40. Remarkably higher efficacy and a wider safety window for nonfrontline over first-line drug combinations in the adenocarcinoma Colo 320DM cell line.
Garza-Trevino EN; Rodriguez-Gonzalez MS; Delgado Gonzalez P; Alonso-Cruz YG; Alonso-Cruz YG; Soto-Dominguez A; Gonzalez Guerrero JF; Castro-Govea Y; Michel Sanchez E; Said Fernandez S; Martinez-Rodriguez HG
J BUON; 2017; 22(5):1115-1121. PubMed ID: 29135091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
